Background: Age related macular degeneration is an acquired
degenerative disease that is responsible for severe loss of vision in
elderly people. There are two types: Dry age related macular degeneration
and wet age related macular degeneration. Its treatment has been improved
and tries to be tailored in the future.
Objective: The aim of this review is to summarize the pharmacological
advances in the treatment of age-related macular degeneration.
Method: A PubMed search has been conducted looking for new molecules and
treatments in age related macular degeneration.
Results: Regarding dry AMD there is no effective treatment to reduce its
progression. However, some molecules such as lampalizumab and eculizumab
were under investigation although have shown low efficacy. Herein that to
try to prevent dry AMD progression the most important studies suggested
increasing the antioxidants intake and quitting the smoke habit. On the
hand, wet AMD have more developed treatment. Nowadays the gold standard
treatment is anti-VEGF treatment. However more effective molecules are
currently under investigation.
Conclusion: There are different molecules in research for dry AMD and wet
AMD. This fact could help us to treat our patients with more effective and
lasting drugs but more clinical trials and safety studies are required in
order to achieve an optimal treatment.